documents
Data license: Public Domain (U.S. Government data) · Data source: Federal Register API & Regulations.gov API
227 rows where agency_id = "FDA" and docket_id = "FDA-2017-P-5787" sorted by posted_date descending
This data as json, CSV (advanced)
Suggested facets: subtype, posted_date, posted_month, comment_start_date, posted_date (date), comment_start_date (date), comment_end_date (date), last_modified (date)
document_type 3
- Supporting & Related Material 221
- Other 4
- Notice 2
agency_id 1
- FDA · 227 ✖
| id | agency_id | docket_id | title | document_type | subtype | posted_date ▲ | posted_year | posted_month | comment_start_date | comment_end_date | last_modified | fr_doc_num | open_for_comment | withdrawn | object_id |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| FDA-2017-P-5787-0242 | FDA | None FDA-2017-P-5787 | Final Response Letter from FDA CDER to Post-Finasteride Syndrome Foundation | Other | Response(s) | 2022-06-09T04:00:00Z | 2022 | 6 | 2022-06-09T04:00:00Z | 2022-06-09T11:35:13Z | 0 | 0 | 090000648515084c | ||
| FDA-2017-P-5787-0231 | FDA | None FDA-2017-P-5787 | Melcangi_Methylation of SRD5A2 in CSF of PFS Pts (Endocr Connect 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:07:15Z | 0 | 0 | 0900006484984797 | |||
| FDA-2017-P-5787-0222 | FDA | None FDA-2017-P-5787 | CMDh Recommendation re Anxiety in Propecia SPC_EMA (Apr 2018) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:27:24Z | 0 | 0 | 0900006484984768 | |||
| FDA-2017-P-5787-0223 | FDA | None FDA-2017-P-5787 | Diviccaro_Finasteride, Hippocampal Neurogenesis and Neuroinflammation in Rats (Psychneuroendocrin 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:28:17Z | 0 | 0 | 0900006484984769 | |||
| FDA-2017-P-5787-0230 | FDA | None FDA-2017-P-5787 | Levine_Court let Merck hide secrets (Reuters 9-11-19) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:06:26Z | 0 | 0 | 0900006484984796 | |||
| FDA-2017-P-5787-0232 | FDA | None FDA-2017-P-5787 | Nguyen and Trinh_Suicidality and Psychological AEs w Finasteride (JAMA Derm 2020) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:09:31Z | 0 | 0 | 0900006484984798 | |||
| FDA-2017-P-5787-0241 | FDA | None FDA-2017-P-5787 | Summary of Product Characteristics_ANSM_English (Dec 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:34:25Z | 0 | 0 | 090000648498449a | |||
| FDA-2017-P-5787-0224 | FDA | None FDA-2017-P-5787 | Gulbinovic_Final Assessment Report of PSUR (Sweden MPA 2007) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:29:58Z | 0 | 0 | 0900006484984791 | |||
| FDA-2017-P-5787-0235 | FDA | None FDA-2017-P-5787 | Petition Supplement 2 Post-Finasteride Syndrome Foundation | Notice | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T17:17:17Z | 0 | 0 | 0900006484984494 | |||
| FDA-2017-P-5787-0226 | FDA | None FDA-2017-P-5787 | Kaufman_Finasteride Rx for AGA (J Am Acad Dermatol 1998) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:31:57Z | 0 | 0 | 0900006484984793 | |||
| FDA-2017-P-5787-0228 | FDA | None FDA-2017-P-5787 | Khera and Mirabel_Penile Vascular Abnormalities in PFS (Translat Androl Urol 2020) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:46:53Z | 0 | 0 | 0900006484984794 | |||
| FDA-2017-P-5787-0236 | FDA | None FDA-2017-P-5787 | Propecia Proposed Prescribing Info_Revision Marks (2002) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:27:53Z | 0 | 0 | 0900006484984495 | |||
| FDA-2017-P-5787-0238 | FDA | None FDA-2017-P-5787 | Propecia Summary of Product Characteristics_MHRA UK (Jun 2018) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:29:49Z | 0 | 0 | 0900006484984497 | |||
| FDA-2017-P-5787-0240 | FDA | None FDA-2017-P-5787 | Reminder of Risk of Psychiatric and Sexual Disorders_ANSM webpage (Feb 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:33:26Z | 0 | 0 | 0900006484984499 | |||
| FDA-2017-P-5787-0237 | FDA | None FDA-2017-P-5787 | Propecia Summary of Product Characteristics_ANSM France (Dec 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:28:52Z | 0 | 0 | 0900006484984496 | |||
| FDA-2017-P-5787-0225 | FDA | None FDA-2017-P-5787 | Irwig_Finasteride and Suicide Case Series (Dermatol 2020) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:30:45Z | 0 | 0 | 0900006484984792 | |||
| FDA-2017-P-5787-0229 | FDA | None FDA-2017-P-5787 | Letter to Health Professionals_Reminder of Risk of Psychiatric and Sexual Disorders_ANSM France (Feb 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:52:35Z | 0 | 0 | 0900006484984795 | |||
| FDA-2017-P-5787-0227 | FDA | None FDA-2017-P-5787 | Godar and Bortolato_Finasteride Reduces Response to Stressful and Rewarding Stimuli (Biomolec 2019) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T15:41:44Z | 0 | 0 | 0900006484984790 | |||
| FDA-2017-P-5787-0233 | FDA | None FDA-2017-P-5787 | Periodic Safety Update Report _19_Merck (Nov 2006) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:24:23Z | 0 | 0 | 0900006484984799 | |||
| FDA-2017-P-5787-0234 | FDA | None FDA-2017-P-5787 | Petition Supplement 1 Post-Finasteride Syndrome Foundation | Notice | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T17:16:41Z | 0 | 0 | 0900006484984493 | |||
| FDA-2017-P-5787-0239 | FDA | None FDA-2017-P-5787 | Red Hand Letter re Finasteride_BfArM Germany (Jul 2018) | Supporting & Related Material | Background Material | 2020-12-03T05:00:00Z | 2020 | 12 | 2020-12-03T16:30:50Z | 0 | 0 | 0900006484984498 | |||
| FDA-2017-P-5787-0221 | FDA | None FDA-2017-P-5787 | Interim Response from FDA to Post-Finasteride Syndrome Foundation | Other | Response(s) | 2018-03-16T04:00:00Z | 2018 | 3 | 2018-03-16T04:00:00Z | 2018-03-16T12:56:22Z | 0 | 0 | 090000648301baba | ||
| FDA-2017-P-5787-0205 | FDA | None FDA-2017-P-5787 | Table of Contents re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | List | 2017-09-28T04:00:00Z | 2017 | 9 | 2017-09-29T12:56:49Z | 0 | 0 | 0900006482b732fe | |||
| FDA-2017-P-5787-0065 | FDA | None FDA-2017-P-5787 | Reference 63 Hamilton_Male Hormone Stimulation and Baldness (Amer J Anat 1942) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:52:33Z | 0 | 0 | 0900006482b65d56 | |||
| FDA-2017-P-5787-0117 | FDA | None FDA-2017-P-5787 | Reference 115 MedWatch FDA Form 3500_PFSS#7 continued (30-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:06Z | 0 | 0 | 0900006482b65dbe | |||
| FDA-2017-P-5787-0119 | FDA | None FDA-2017-P-5787 | Reference 117 MedWatch FDA Form 3500_PFSS#8 continued (28-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:12Z | 0 | 0 | 0900006482b65dc0 | |||
| FDA-2017-P-5787-0007 | FDA | None FDA-2017-P-5787 | Reference 5 Andersson_Cloned human and rat steroid 5α-reductases (PNAS 1990) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:44:54Z | 0 | 0 | 0900006482b650a9 | |||
| FDA-2017-P-5787-0011 | FDA | None FDA-2017-P-5787 | Reference 9 Antiandrogen Drugs Definition (Free Online Medical Dictionary, Thesaurus and Encyclopedia 2013) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:45:18Z | 0 | 0 | 0900006482b658b5 | |||
| FDA-2017-P-5787-0030 | FDA | None FDA-2017-P-5787 | Reference 28 Castro-Magana_Finasteride and Human Testicular Steroidogenesis (J Androl 1996) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:50:07Z | 0 | 0 | 0900006482b658d9 | |||
| FDA-2017-P-5787-0165 | FDA | None FDA-2017-P-5787 | Reference 163 Schultheiss_AR and ER in Human Corpus Cavernosum (World J Urol 2003) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:59:15Z | 0 | 0 | 0900006482b65e86 | |||
| FDA-2017-P-5787-0191 | FDA | None FDA-2017-P-5787 | Reference 189 Trybek_AR in the Epididymis of Rats with DHT Deficiency (Reprod Biol 2005) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:01:01Z | 0 | 0 | 0900006482b65ebe | |||
| FDA-2017-P-5787-0021 | FDA | None FDA-2017-P-5787 | Reference 19 Bruchovsky_Intranuclear Binding of T in Rat Prostate (J Biol Chem 1968) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:49:28Z | 0 | 0 | 0900006482b65920 | |||
| FDA-2017-P-5787-0023 | FDA | None FDA-2017-P-5787 | Reference 21 Bull_Mechanism-Based Inhibition of Human 5AR (J Am Chem Soc 1996) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:49:37Z | 0 | 0 | 0900006482b65922 | |||
| FDA-2017-P-5787-0106 | FDA | None FDA-2017-P-5787 | Reference 104 MedWatch FDA Form 3500_PFSS#2 3500 (24-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:55:19Z | 0 | 0 | 0900006482b65ab0 | |||
| FDA-2017-P-5787-0115 | FDA | None FDA-2017-P-5787 | Reference 113 MedWatch FDA Form 3500_PFSS#6 continued (29-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:55:59Z | 0 | 0 | 0900006482b65acd | |||
| FDA-2017-P-5787-0116 | FDA | None FDA-2017-P-5787 | Reference 114 MedWatch FDA Form 3500_PFSS#7 (30-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:03Z | 0 | 0 | 0900006482b65ace | |||
| FDA-2017-P-5787-0129 | FDA | None FDA-2017-P-5787 | Reference 127 Nonomura_Androgen Binding in Mammalian Penis (J Urol 1990) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:47Z | 0 | 0 | 0900006482b65afe | |||
| FDA-2017-P-5787-0184 | FDA | None FDA-2017-P-5787 | Reference 182 Tindall_5ARIs in PC (J Urol 2008) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:00:26Z | 0 | 0 | 0900006482b65b79 | |||
| FDA-2017-P-5787-0029 | FDA | None FDA-2017-P-5787 | Reference 27 Castelli_Regional Distribution of 5AR2 in Rat Brain_Table 1 (Psychoneuroendocrin 2013) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:50:02Z | 0 | 0 | 0900006482b658d8 | |||
| FDA-2017-P-5787-0157 | FDA | None FDA-2017-P-5787 | Reference 155 Roberts_Clinical Dose Ranging Studies w Finasteride for MPHL (J Am Acad Dermatol 1999) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:58:46Z | 0 | 0 | 0900006482b65e58 | |||
| FDA-2017-P-5787-0075 | FDA | None FDA-2017-P-5787 | Reference 73 Irwig_Finasteride and Persistent Sexual Side Effects (J Sex Med 2011) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:53:18Z | 0 | 0 | 0900006482b65a24 | |||
| FDA-2017-P-5787-0087 | FDA | None FDA-2017-P-5787 | Reference 85 Ko_CDER Medical Review_NDA 20-788_P3 (Dec-1997) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:54:02Z | 0 | 0 | 0900006482b65a87 | |||
| FDA-2017-P-5787-0198 | FDA | None FDA-2017-P-5787 | Reference 196 Wessells_PLESS_Sexual AEs in BPH (Urology 2003) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:01:25Z | 0 | 0 | 0900006482b65ba8 | |||
| FDA-2017-P-5787-0201 | FDA | None FDA-2017-P-5787 | Reference 199 Wu_Reproductive AEs w Alopecia Drugs (Oncotarget 2016) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:01:35Z | 0 | 0 | 0900006482b65bab | |||
| FDA-2017-P-5787-0141 | FDA | None FDA-2017-P-5787 | Reference 139 Presti_Finasteride for Stage D PC (J Urol 1992) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:35Z | 0 | 0 | 0900006482b65e1e | |||
| FDA-2017-P-5787-0101 | FDA | None FDA-2017-P-5787 | Reference 99 Mantzoros_DHT and Male Sexual Behavior (BMJ 1995) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:55:02Z | 0 | 0 | 0900006482b65aab | |||
| FDA-2017-P-5787-0134 | FDA | None FDA-2017-P-5787 | Reference 132 Park_Androgens and NOS mRNA in Rat Corpus Cavernosum (BJU Int 1999) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:07Z | 0 | 0 | 0900006482b65b03 | |||
| FDA-2017-P-5787-0145 | FDA | None FDA-2017-P-5787 | Reference 143 Propecia Full Prescribing Info (31-Jan-2014) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:51Z | 0 | 0 | 0900006482b65b27 | |||
| FDA-2017-P-5787-0178 | FDA | None FDA-2017-P-5787 | Reference 176 Suzuki_PK and Binding of Finasteride to 5AR1 and 5AR2 (Drug Metab Pharmacokin 2010) | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:00:04Z | 0 | 0 | 0900006482b65b73 | |||
| FDA-2017-P-5787-0179 | FDA | None FDA-2017-P-5787 | Reference 177 Tay_Finasteride in Adenoca of Prostate (Ann Onc 2004) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:00:08Z | 0 | 0 | 0900006482b65b74 | |||
| FDA-2017-P-5787-0139 | FDA | None FDA-2017-P-5787 | Reference 137 Poletti_Androgen Activating Enzymes in CNS (J Steroid Biochem Mol Biol 1999) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:28Z | 0 | 0 | 0900006482b65e1c | |||
| FDA-2017-P-5787-0143 | FDA | None FDA-2017-P-5787 | Reference 141 Propecia Full Prescribing Info (8-Dec-2001) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:43Z | 0 | 0 | 0900006482b65e20 | |||
| FDA-2017-P-5787-0071 | FDA | None FDA-2017-P-5787 | Reference 69 Imperato-McGinley_C19 and C21 Metabolites w Finasteride and 5AR2 Deficiency (JCEM 1990) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:53:04Z | 0 | 0 | 0900006482b65a20 | |||
| FDA-2017-P-5787-0057 | FDA | None FDA-2017-P-5787 | Reference 55 Glina_Finasteride and Infertility (Rev Hosp Clin 2004) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:52:04Z | 0 | 0 | 0900006482b65d4e | |||
| FDA-2017-P-5787-0060 | FDA | None FDA-2017-P-5787 | Reference 58 Gormley_Treating AGA with 5-Alpha Reductase Inhibitors_U.S. Patent # 5,547,957 (20-Aug-1996) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:52:15Z | 0 | 0 | 0900006482b65d51 | |||
| FDA-2017-P-5787-0012 | FDA | None FDA-2017-P-5787 | Reference 10 Aumuller_Localization of 5AR Isoenzymes in Human Tissue (Acta Anat 1996) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:45:22Z | 0 | 0 | 0900006482b658b6 | |||
| FDA-2017-P-5787-0028 | FDA | None FDA-2017-P-5787 | Reference 26 Castelli_Regional Distribution of 5AR2 in Rat Brain (Psychoneuroendocrin 2013) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:49:59Z | 0 | 0 | 0900006482b658d7 | |||
| FDA-2017-P-5787-0054 | FDA | None FDA-2017-P-5787 | Reference 52 Geller_Castration-Like Effects of Finasteride on Prostate (J Cell Biochem 1992) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:51:52Z | 0 | 0 | 0900006482b659f2 | |||
| FDA-2017-P-5787-0069 | FDA | None FDA-2017-P-5787 | Reference 67 Imperato-McGinley_5AR Deficiency and Pseudohermaphrotism (Science 1974) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:52:57Z | 0 | 0 | 0900006482b65a1e | |||
| FDA-2017-P-5787-0093 | FDA | None FDA-2017-P-5787 | Reference 91 Labrie_Serum Steroid Precursors and Androgen Metabolites (J Clin Endocrinol Metab 1997) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:54:33Z | 0 | 0 | 0900006482b65a8d | |||
| FDA-2017-P-5787-0199 | FDA | None FDA-2017-P-5787 | Reference 197 Whiting_Finasteride 1 mg in MPHL age 41-60 (Eur J Dermotol 2003) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:01:28Z | 0 | 0 | 0900006482b65ba9 | |||
| FDA-2017-P-5787-0202 | FDA | None FDA-2017-P-5787 | Reference 200 Yamana_Type 3 5AR inhibition by finasteride and dutasteride (Horm Mol Clin Invest 2010) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:01:38Z | 0 | 0 | 0900006482b65bac | |||
| FDA-2017-P-5787-0098 | FDA | None FDA-2017-P-5787 | Reference 96 Lugg_DHT and NO Penile Erection in the the Rat (Endocrin 1995) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:54:50Z | 0 | 0 | 0900006482b65aa8 | |||
| FDA-2017-P-5787-0111 | FDA | None FDA-2017-P-5787 | Reference 109 MedWatch FDA Form 3500_PFSS#4 continued (26-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:55:46Z | 0 | 0 | 0900006482b65ac9 | |||
| FDA-2017-P-5787-0127 | FDA | None FDA-2017-P-5787 | Reference 125 Moore_Finasteride and Uncertainty in Establishing Harm (JAMA Derm 2015) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:39Z | 0 | 0 | 0900006482b65afa | |||
| FDA-2017-P-5787-0131 | FDA | None FDA-2017-P-5787 | Reference 129 O'Donnell_T-Dependent Spermatogenesis in Rats and 5ARI (J Androl 1999) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:56Z | 0 | 0 | 0900006482b65b00 | |||
| FDA-2017-P-5787-0152 | FDA | None FDA-2017-P-5787 | Reference 150 Rittmaster_Adiol-G in Liver, Skin and Prostate (JCEM 1993) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:58:25Z | 0 | 0 | 0900006482b65b2e | |||
| FDA-2017-P-5787-0180 | FDA | None FDA-2017-P-5787 | Reference 178 The Pharma Letter_FDA C'tee Raises Concerns Over Merck's Propecia (11-19-97) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:00:11Z | 0 | 0 | 0900006482b65b75 | |||
| FDA-2017-P-5787-0181 | FDA | None FDA-2017-P-5787 | Reference 179 The Pharma Letter_Propecia Approved in US for MPB (1-12-98) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:00:15Z | 0 | 0 | 0900006482b65b76 | |||
| FDA-2017-P-5787-0086 | FDA | None FDA-2017-P-5787 | Reference 84 Ko_CDER Medical Review_NDA 20-788_P2 (Dec-1997) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:54:00Z | 0 | 0 | 0900006482b65d81 | |||
| FDA-2017-P-5787-0121 | FDA | None FDA-2017-P-5787 | Reference 119 Melcangi_CSF Neurosteroid Levels in PFS (JSM 2013) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:19Z | 0 | 0 | 0900006482b65dc2 | |||
| FDA-2017-P-5787-0128 | FDA | None FDA-2017-P-5787 | Reference 126 Nickel_PROSPECT Study in BPH (Can Med Assoc J 1996)_ re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:43Z | 0 | 0 | 0900006482b65afd | |||
| FDA-2017-P-5787-0146 | FDA | None FDA-2017-P-5787 | Reference 144 Propecia Selected Safety Information - Not an Antiandrogen (Propecia Website 10-5-08) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:55Z | 0 | 0 | 0900006482b65b28 | |||
| FDA-2017-P-5787-0003 | FDA | None FDA-2017-P-5787 | Reference 1 Ali_Pharmacovigil of Persistent SD and Suicidal Ideation w Finasteride (Pharmacother 2015) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:44:39Z | 0 | 0 | 0900006482b650a5 | |||
| FDA-2017-P-5787-0015 | FDA | None FDA-2017-P-5787 | Reference 13 Basaria_Characteristics of Men w Persistent SD after Finasteride for AGA_supplementary appendix (JCEM 2016) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:45:33Z | 0 | 0 | 0900006482b658b9 | |||
| FDA-2017-P-5787-0017 | FDA | None FDA-2017-P-5787 | Reference 15 Belelli_Neurosteroids and the GABA-A Receptor (Nat Rev Neurosci 2005) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:45:39Z | 0 | 0 | 0900006482b658bb | |||
| FDA-2017-P-5787-0032 | FDA | None FDA-2017-P-5787 | Reference 30 Celotti_Steroid Metabolism in the Mammalian Brain (Brain Res Bull 1997) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:50:21Z | 0 | 0 | 0900006482b658db | |||
| FDA-2017-P-5787-0034 | FDA | None FDA-2017-P-5787 | Reference 32 Charmandari_DHT Administration in Children (Horm Res 2001) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:50:28Z | 0 | 0 | 0900006482b658dd | |||
| FDA-2017-P-5787-0162 | FDA | None FDA-2017-P-5787 | Reference 160 Sawaya_Novel Agents for the Treatment of Alopecia (Semin Cut Med Surg 1998) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:59:04Z | 0 | 0 | 0900006482b65e5d | |||
| FDA-2017-P-5787-0169 | FDA | None FDA-2017-P-5787 | Reference 167 Shukla_Finasteride Analysis of Comparative of Pharmacodynamic effects of 1 mg and 5 mg Finasteride Dose_ ID 3046462 (1-Jun-2011) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:59:29Z | 0 | 0 | 0900006482b65e8a | |||
| FDA-2017-P-5787-0053 | FDA | None FDA-2017-P-5787 | Reference 51 Gao_Chemistry and Structural Biology of AR (Chem Rev 2005) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:51:49Z | 0 | 0 | 0900006482b659f1 | |||
| FDA-2017-P-5787-0055 | FDA | None FDA-2017-P-5787 | Reference 53 Giatti_Effects of Subchronic Finasteride Rx and Withdrawal in Male Rat Brain (Neuroendocrin 2015) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:51:56Z | 0 | 0 | 0900006482b659f3 | |||
| FDA-2017-P-5787-0072 | FDA | None FDA-2017-P-5787 | Reference 70 Ioannidis_Safety Reporting in RCTs (JAMA 2001) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:53:08Z | 0 | 0 | 0900006482b65a21 | |||
| FDA-2017-P-5787-0074 | FDA | None FDA-2017-P-5787 | Reference 72 Irwig_Depressive and Suicidal Sx in PFS (J Clin Psych 2012) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:53:15Z | 0 | 0 | 0900006482b65a23 | |||
| FDA-2017-P-5787-0096 | FDA | None FDA-2017-P-5787 | Reference 94 Lewis_Effect of Androgen on Penile Tissue (Endocrine 2004) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:54:43Z | 0 | 0 | 0900006482b65a90 | |||
| FDA-2017-P-5787-0204 | FDA | None FDA-2017-P-5787 | Reference 202 Zhang_Finasteride and ED in Rat Model (J Sex Med 2012) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:01:45Z | 0 | 0 | 0900006482b65bae | |||
| FDA-2017-P-5787-0140 | FDA | None FDA-2017-P-5787 | Reference 138 Prescriber Update_Post Finasteride Syndrome (New Zealand 29-Apr-2016) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:32Z | 0 | 0 | 0900006482b65e1d | |||
| FDA-2017-P-5787-0158 | FDA | None FDA-2017-P-5787 | Reference 156 Romer_Finasteride Inhibits Hippocampal Neurogenesis in Mice (Pharmacopsych 2010) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:58:49Z | 0 | 0 | 0900006482b65e59 | |||
| FDA-2017-P-5787-0159 | FDA | None FDA-2017-P-5787 | Reference 157 Ruizeveld de Winter_AR Expression in Human Tissues (J Histochem Cytochem 1991) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:58:53Z | 0 | 0 | 0900006482b65e5a | |||
| FDA-2017-P-5787-0190 | FDA | None FDA-2017-P-5787 | Reference 188 Traish_Glucose, Lipids and SD w Dutasteride for BPH (Horm Mol Biol Clin Invest 2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T21:00:50Z | 0 | 0 | 0900006482b65ebd | |||
| FDA-2017-P-5787-0059 | FDA | None FDA-2017-P-5787 | Reference 57 Gormley_MK-906 and Circulating Androgens (J Clin Endocr Metab 1990) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:52:11Z | 0 | 0 | 0900006482b65d50 | |||
| FDA-2017-P-5787-0118 | FDA | None FDA-2017-P-5787 | Reference 116 MedWatch FDA Form 3500_PFSS#8 (28-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:09Z | 0 | 0 | 0900006482b65dbf | |||
| FDA-2017-P-5787-0105 | FDA | None FDA-2017-P-5787 | Reference 103 MedWatch FDA Form 3500_PFSS#1 continued (24-May-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:55:16Z | 0 | 0 | 0900006482b65aaf | |||
| FDA-2017-P-5787-0132 | FDA | None FDA-2017-P-5787 | Reference 130 Overstreet_Finasteride, Spermatogenesis and Semen Production (J Urol 1999) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:57:00Z | 0 | 0 | 0900006482b65b01 | |||
| FDA-2017-P-5787-0151 | FDA | None FDA-2017-P-5787 | Reference 149 Rasmusson_Treating AGA with Finasteride _U.S. Patent # 5,571,817 (5-Nov-1996) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:58:22Z | 0 | 0 | 0900006482b65b2d | |||
| FDA-2017-P-5787-0153 | FDA | None FDA-2017-P-5787 | Reference 151 Rittmaster_Apoptosis of Prostate in Men given Finasteride (JCEM 1996) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:58:29Z | 0 | 0 | 0900006482b65b2f | |||
| FDA-2017-P-5787-0061 | FDA | None FDA-2017-P-5787 | Reference 59 Grino_Phase III Studies of Finasteride for BPH (Eur Urol 1994) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:52:18Z | 0 | 0 | 0900006482b65d52 | |||
| FDA-2017-P-5787-0085 | FDA | None FDA-2017-P-5787 | Reference 83 Ko_CDER Medical Review_NDA 20-788_P1 (Dec-1997) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:53:56Z | 0 | 0 | 0900006482b65d80 | |||
| FDA-2017-P-5787-0125 | FDA | None FDA-2017-P-5787 | Reference 123 MK-906 Protocol_PLESS Trial (20-Nov-1991) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:56:33Z | 0 | 0 | 0900006482b65dc6 | |||
| FDA-2017-P-5787-0005 | FDA | None FDA-2017-P-5787 | Reference 3 Amendments to Propecia Mktg Authorisation (CMDh Apr-2017) re Citizen Petition Post- Finasteride Syndrome Foundation | Supporting & Related Material | Background Material | 2017-09-21T04:00:00Z | 2017 | 9 | 2017-09-21T20:44:47Z | 0 | 0 | 0900006482b650a7 |
Advanced export
JSON shape: default, array, newline-delimited, object
CREATE TABLE documents (
id TEXT PRIMARY KEY,
agency_id TEXT,
docket_id TEXT REFERENCES dockets(id),
title TEXT,
document_type TEXT,
subtype TEXT,
posted_date TEXT,
posted_year INTEGER,
posted_month INTEGER,
comment_start_date TEXT,
comment_end_date TEXT,
last_modified TEXT,
fr_doc_num TEXT,
open_for_comment INTEGER,
withdrawn INTEGER,
object_id TEXT
);
CREATE INDEX idx_docs_agency ON documents(agency_id);
CREATE INDEX idx_docs_docket ON documents(docket_id);
CREATE INDEX idx_docs_date ON documents(posted_date);
CREATE INDEX idx_docs_year ON documents(posted_year);
CREATE INDEX idx_docs_type ON documents(document_type);
CREATE INDEX idx_docs_frnum ON documents(fr_doc_num);
CREATE INDEX idx_docs_comment_end ON documents(comment_end_date) WHERE comment_end_date IS NOT NULL AND withdrawn = 0;